IBB240712C137000
- 1.12
- +0.40+55.56%
iShares Biotechnology ETF Newsroom
Reported Earlier, Moderna And Mitsubishi Tanabe Pharma Partner To Promote MRNA Respiratory Vaccine Portfolio In Japan
Under the agreement, Moderna will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines. Both companies will engage in activities to enable broad access
This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Sector Update: Health Care Stocks Edge Higher Premarket Monday
Health care stocks were edging higher premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was advancing 0.1% and the iShares Biotechnology ETF (IBB) was up 0.6% recently.Morphic Holding
Today's Morning Movers and Top Ratings: TSLA, PNC, SEDG, GLW and More
PNC Financial Services shares gained 1.21% upon receiving an upgrade by UBS to buy from neutral, with UBS citing the regional bank's potential for growth as loan demand shows signs of improvement.
Exchange-Traded Funds, Equity Futures Edge Up Pre-Bell Monday Ahead of Powell Testimony, Inflation Data
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.03% and the actively traded Invesco QQQ Trust (QQQ) was 0.1% higher in Monday's premarket activity, ahead of key inflation d
Ideaya Stock Jumps After Positive Study Data From Cancer Study
Regeneron Pharmaceuticals Expects Its Q2 GAAP And Non-GAAP Financial Results Will Include A Pre-tax Charge Of ~$24M For Acquired In-process Research And Development, Impacting GAAP And Non-GAAP EPS By About $0.18 - 8K
Regeneron Pharmaceuticals Expects Its Q2 GAAP And Non-GAAP Financial Results Will Include A Pre-tax Charge Of ~$24M For Acquired In-process Research And Development, Impacting GAAP And Non-GAAP EPS By
Gilead Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 35.91% Raymond James → $93 Upgrades Market Perform → Outperform 07/01/2024 8.14% RBC Capital $7
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga.
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
Unpacking the Latest Options Trading Trends in Moderna
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA).And retail traders should know.We noticed this today when the trades showed up on publicly available options
Sector Update: Health Care Stocks Steady Premarket Friday
Health care stocks were steady premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) inactive. Bain Capital and Cinven are considering a potential jo
Exchange-Traded Funds Edge Higher, Equity Futures Mixed Pre-Bell Friday as Investors Await Hints About Potential Rate Cuts
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.04% and the actively traded Invesco QQQ Trust (QQQ) was 0.1% higher in Friday's premarket activity, as investors wait for th
AI Has 'The Hallmarks Of An Inflating Bubble,' Warns Veteran Wall Street Investor
Signs are emerging that the market boom surrounding artificial intelligence (AI) might be taking on the characteristics of a bubble.
Here's How Much $1000 Invested In Moderna 5 Years Ago Would Be Worth Today
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 37.68% on an annualized basis producing an average annual return of 50.84%. Currently, Moderna has a market capitalization of
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 1.82% on an annualized basis producing an average annual return of 12.66%. Currently, Regeneron Pharmaceut
Lilly's New Alzheimer's Drug Could Generate $7.1B in Sales: Analyst
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June's sharply lower-than-expected services sector activ
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
On Tuesday, the FDA approved Eli Lilly and Co's (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.Once-monthly, Kisunla is th
What's Going On With Moderna Stock Wednesday
Moderna, Inc. (NASDAQ:MRNA) shares are trending on Wednesday.